ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Nasal Polyps
Rhinosinusitis
Allergic Rhinitis
Rhinitis
Sinusitis
Respiration Disorders

Asthma trials near Madrid, MD, ESP:

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (ARRIVAL)

administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..Study det...

Enrolling
Severe Asthma
Combination Product: Budesonide/formoterol
Combination Product: Mannitol

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 83 other locations

in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations ...

Enrolling
Asthma
Drug: Placebo
Drug: Benralizumab

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 83 other locations

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will e...

Enrolling
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

Phase 2

Upstream Bio

Madrid, Spain and 122 other locations

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled co...

Enrolling
Asthma
Biological: Tezepelumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Madrid, Spain and 115 other locations

to budesonide in children from 6 to less than 12 years of age with asthma.* The study duration will be up to 37 weeks including an investiga...

Enrolling
Asthma
Drug: QMF149
Drug: Budesonide

Phase 3

Novartis
Novartis

Madrid, Spain and 51 other locations

BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma...

Enrolling
Asthma
Drug: AZD4604
Other: Placebo

Phase 2

AstraZeneca
AstraZeneca

Madrid, Spain and 158 other locations

treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted i...

Enrolling
Asthma
Wheezing
Drug: Placebo
Drug: Dupilumab

Phase 3

Sanofi
Sanofi

Madrid, Madrid, Comunidad De, Spain and 57 other locations

and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma...

Enrolling
Asthma, Allergic
Rhinoconjunctivitis
Other: Placebo
Biological: 30,000 MG01 + 10,000 T517

Phase 3

Inmunotek

Madrid, Spain and 25 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Atuliflapon
Drug: Placebo

Phase 2

AstraZeneca
AstraZeneca

Madrid, Spain and 381 other locations

propellant (HFA-152a) compared to the currently approved one (HFA-134a) in the medication (CHF5993) in patients with moderate to severe asthma...

Active, not recruiting
Asthma
Drug: CHF5993 200/6/12.5 μg pMDI HFA-152a
Drug: Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

Phase 3

Chiesi
Chiesi

Madrid, Spain and 142 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems